Clinical trial data also suggest a renoprotective effect of both GLP-1 receptor agonists and SGLT2 inhibitors in patients with diabetes, which may contribute to their CV benefits [120–123]. The gene discussed is SLC5A2; the disease is diabetes mellitus.